Modern Pathology · 2018 · 46 citations · 47 references
MedicineImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyCancer BiomarkersImmuno-oncology BiomarkersMolecular Classification Of TumorsTumor AntigensTumor ImmunopathologyTumor-associated AntigensCancer-associated ImmunosuppressionCd8+ Tumor-infiltrating LymphocytesHla Class I MoleculesImmunosuppressive MicroenvironmentLung AdenocarcinomaProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 UpregulationTissue Microarrays
47
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text
Medicine, Oncology, Pharmacology +13